Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017152796) APPLICATION OF OBACUNONE IN PREPARATION OF DRUG FOR PREVENTING AND TREATING LUNG DAMAGE AND PULMONARY FIBROSIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/152796 International Application No.: PCT/CN2017/075179
Publication Date: 14.09.2017 International Filing Date: 28.02.2017
IPC:
A61K 31/585 (2006.01) ,A61P 11/00 (2006.01)
[IPC code unknown for A61K 31/585][IPC code unknown for A61P 11]
Applicants:
广东省中医院 GUANGDONG PROVINCIAL HOSPITAL OF TRADITIONAL CHINESE MEDICINE [CN/CN]; 中国广东省广州市 越秀区大德路111号徐洋 Xu, Yang No. 111 Dade Road, Yuexiu District Guangzhou, Guangdong 510006, CN
Inventors:
徐洋 XU, Yang; CN
徐胜梅 XU, Shengmei; CN
陈为民 CHEN, Weimin; CN
Agent:
广州市天河庐阳专利事务所(普通合伙) GUANGZHOU TIANHE LUYANG PATENT OFFICE (GENERAL PARTNERSHIP); 中国广东省广州市 天河东路242号802之一室胡济元 JiyuanHu Room 802, No. 242, East Tianhe Road Guangzhou, Guangdong 510620, CN
Priority Data:
201610133807.109.03.2016CN
Title (EN) APPLICATION OF OBACUNONE IN PREPARATION OF DRUG FOR PREVENTING AND TREATING LUNG DAMAGE AND PULMONARY FIBROSIS
(FR) APPLICATION DE L'OBACUNONE DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LA PRÉVENTION ET LE TRAITEMENT DE LÉSIONS PULMONAIRES ET DE LA FIBROSE PULMONAIRE
(ZH) 黄柏酮在制备防治肺损伤和肺纤维化的药物中的应用
Abstract:
(EN) An application of obacunone in preparation of a drug for use in preventing and treating lung damage and pulmonary fibrosis, the drug consisting of obacunone and pharmaceutically acceptable excipients and additives, and the mass percentage of the obacunone in the drug is 3-25%. The obacunone in the drug can inhibit Bleomycin-induced lung damage and pulmonary fibrosis in mice, and regulate the expression of the inflammation-related lymphokine in the Bleomycin-induced damaged lung tissue in mice.
(FR) L'invention concerne une application de l'obacinone dans la préparation d'un médicament destiné à une utilisation dans la prévention et le traitement de lésions pulmonaires et de la fibrose pulmonaire, le médicament étant constitué d'obacinone et d'excipients et additifs pharmaceutiquement acceptables, le pourcentage en masse d'obacinone contenu dans le médicament étant compris entre 3 et 25 %. L'obacinone contenu dans le médicament peut inhiber chez la souris les lésions pulmonaires et la fibrose pulmonaire induites par la bléomycine, et réguler chez la souris l'expression de lymphokines inflammatoires au niveau des lésions du tissu pulmonaire induites par la bléomycine.
(ZH) 黄柏酮在制备防治肺损伤和肺纤维化的药物中的应用,该药物由黄柏酮和药学上可接受的辅料和添加剂组成,其中黄柏酮在药物中的质量百分含量为3-25%。该药物中的黄柏酮可抑制Bleomycin诱导的小鼠肺损伤及肺纤维化,调节Bleomycin诱导的小鼠肺损伤组织的炎性相关的淋巴因子表达。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)